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Male breast cancer (MBC) is rare, and research on the predictors of MBC has been 
limited because of inadequate funding in and outside of the United States. One goal of 
this study was to eradicate the stereotyping of breast cancer as a female disease. The 
emergence of medical technology and education to benefit the public will help to ensure 
greater health awareness at the individual, community, and global levels. The purpose of 
this study was to understand the influence of the predictors of age; race (Black, White, 
and Other); and grade of cancer (I, II, or III) on the outcome of mastectomy in MBC. The 
study was guided by the social determinants of health model. A quantitative approach 
was used to analyze archival data from 2011 to 2013 in the Surveillance Epidemiology 
and End Results (SEER) database using SPSS v.23. Data from 427 MBC patients ages 18 
years and older from the United States comprised the sample. The SEER data were 
analyzed using logistic regression analysis. Results showed that of the 427 cases of MBC 
that were analyzed, 55 had a diagnosis of Grade I, 190 had a diagnosis of Grade II, and 
182 had a diagnosis of Grade III. For 3 years, 116 men had undergone mastectomy. 
Grade I cancer, Grade II cancer, and Grade III cancer were statistically insignificant 
predictors of mastectomy; however, age, race was a statistically significant predictor of 
mastectomy among White men with MBC. The results will contribute to social change 
initiatives by educating the public about the predictors of mastectomy in MBC patients. 
The results also will increase the current knowledge base by informing the public, clinical 
professionals, and patients about the relationship of the predictors of age; race; and grade 
of cancer (I, II, or III) on the outcome of mastectomy in MBC.  
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Chapter 1: Introduction to the Study  
Introduction 
Male breast cancer (MBC) occurs infrequently, and research focusing on MBC 
has been limited because of inadequate funding within and outside the United States 
(Chavez-MacGregor, Clarke, Lichtensztajn, Hortobagyi, & Giordano, 2013; Kornegoor 
et al., 2012). The incidence of MBC is rising, and men across the globe are continuing to 
die from MBC. Chapter 1 introduces the topic, provides background information about 
MBC, and includes a statement of the problem. The purpose of the study and the 
theoretical/conceptual framework and nature of the study are defined, and the limitations 
and delimitations of the study are examined. In addition, the chapter includes the 
assumptions, scope, and significance of the study. The research questions (RQs) are 
provided, and a summary concludes the chapter. The purpose of this study was to 
understand the influence of the predictors of age; race; and grade of cancer (I, II, or III) 
on the outcome of mastectomy in MBC. The results will contribute to the literature and 
will support social change initiatives by educating the public about the predictors of 
mastectomy in MBC patients. 
Background 
MBC is an uncommon disease whose occurrence often is overlooked, thus leading 
to more advanced stages (American Cancer Society [ACS], 2012). Because of the late 
diagnosis and known rarity of MBC, one could argue that exploring the predictors of it is 
not crucial, despite the number of men dying from MBC (Sandhu et al., 2012). A man’s 
risk of developing breast cancer in his lifetime is about one in 1,000 (ACS, 2012).  
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According to the National Cancer Institute (NCI, 2016a), approximately 249,260 
new cases of female breast cancer and 2,600 new cases of MBC occur annually in the 
United States. The NCI (2016b) estimated that in 2016, 440 men would die from the 
disease in the United States and that in Texas alone, 132 men would be diagnosed with 
MBC in that same year, with 28 of them dying from the disease. In the United Kingdom, 
about 240 men are diagnosed with MBC annually (Kipling, Ralph, & Callanan, 2014). 
Globally, research has shown that the incidence of MBC is higher in several regions of 
Africa; for example, Zambia has a rate of 15%, and Egypt and Tanzania have rates of 
6%, respectively (“Male Breast Cancer Numbers Rising Most Fail to Spot It Until It Has 
Spread to Lymph Nodes,” 2004).   
Role of Society and Acceptance of MBC 
Social change plays a vital role in encouraging men to undergo the same annual 
mammogram screening that women have been supporting for years. Like women, men 
need to be screened, diagnosed, and treated to reduce the morbidity and mortality rates of 
the disease (Centers for Disease Control and Prevention [CDC], 2012b); Fentiman, 
Fourquet, & Hortobagyi, 2006; National Institutes of Health [NIH], 2013; NCI, 2013). 
According to Robinson, Metoyer, and Bhayani (2008), breast cancer has always been 
seen as a disease of women in general. Most cases of MBC occur among men between 
the ages of 60 and 70 years (Cutuli, 2009); however, younger men are now being 
diagnosed with MBC (Fentiman et al., 2006; NIH, 2013; Rachid, Yacouba, & Hassane, 
2009). Robinson et al. stated that serious issues remain because of the lack of studies 
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focusing on MBC. They asserted that the gap in knowledge about MBC highlights the 
need for further studies on the impact of this disease on men. 
Brain, Williams, Iredale, France, and Gray (2006) stated that acceptance of the 
disease by men is impeded by the stigma of coping with the disease, altered body image, 
and the unavailability of supportive needs. Robinson et al. (2008) added anxiety and 
depression symptoms to the list. The most significant factor upsetting self-esteem is body 
image (Brain et al., 2006; Burson et al., 2009; Hiatt & Breen, 2008; Rosenbaum et al., 
2004). Individuals in marital relationships might experience distress manifesting as 
decreased satisfaction in terms of intimacy, sexual function, and appreciation of spouse or 
partner (Brain et al., 2006).  
Ahmed, Ukwenya, Abdullahi, and Muhammad (2012) stated that MBC might be 
an exceptional condition representing about 1% of all breast cancers. Ahmed et al. 
evaluated male patients who had a histological diagnosis of breast cancer from 2001 to 
2010. Modified radical mastectomies were performed on those patients after the 
evaluations (Ahmed et al., 2012). 
Mathew, Perkins, Stephens, Middleton, and Yang (2008) explained that MBC 
appears on a mammogram often as a spiculated margin, a noncalcified high-thickness 
mass with an asymmetrical figure located in a subareolar area. It is characterized on a 
sonogram as a hard hypoechoic group and a microlobulated border (Mathew et al., 2008). 
The earliest stages of cancer are referred to as carcinoma in situ (Mathew et al., 2008). 
The finding of this particular cancer in the breast milk duct is called ductal carcinoma in 
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situ, or DCIS, typical in men because of the lack of early screening or early detection 
(Doyle, Steel, & Porter, 2011).  
Staging of MBC 
Members of the health care team initiate staging to determine disease progression 
once there is evidence of a malignant tumor or a diagnosis of breast cancer (NCI, 2013). 
Staging of breast cancer depends on the size of the tumor, the number and location of any 
lymph nodes involved, and whether there has been an effect on other organs, and 
according to the NCI (2013), cancer can be categorized as one of four stages: 
• Stage 0-I: Early detection; cancer cells are confined to a limited area. 
• Stage II: Cancer cells begin to spread around the breast area. 
• Stage III: Cancer cells invade neighboring tissues near the breast. 
• Stage IV: Cancer cells have metastasized to other organs of the body and are 
usually invasive. 
Universally, tumors are graded as I, II, III, or IV, depending on the rate of 
abnormality. The NCI (2013) described the stages as the following: 
• GX: Grade cannot be assessed (undetermined grade). 
• GI: Well differentiated (low grade); appears close to normal. 
• GII: Moderately differentiated (intermediate grade); abnormal cells spread 
slowly. 




• GIV: Undifferentiated (high grade); grow rapidly and spread faster (NCI, 
2013). 
Staging of MBC is crucial because proper assessment of the disease can facilitate 
its early diagnosis and detection, and slow its progress from Stage 0 to more advanced 
stages (CDC, 2012b; Chavez-MacGregor et al., 2013; Ginossar, 2008; National Breast 
Cancer Awareness Month, 2010; NCI, 2013). Kanthan, Fried, Rueckl, Senger, and 
Kanthan (2010) stated that MBC can impact all segments of the male population, 
regardless of socioeconomic (SES) class and age. MBC is a rare yet potentially 
destructive disease with little known risk factors (Kanthan et al., 2010).  
Proper assessment and staging, along with early diagnosis and detection, can slow 
the progress of MBC to later stages of the disease (Ginossar, 2008). MBC usually 
presents with a palpable, unilateral, and painless subareolar mass (Fentiman et al., 2006) 
that often is located away from the nipple (Doyle et al., 2011; Fentiman et al., 2006; NIH, 
2013). Twenty-nine percent of MBC patients diagnosed with invasive ductal cancer 
undergo surgery (“Breast,” 2013). Seventeen percent of other MBC patients discovered 
with tumors, particularly unadulterated DCIS, have surgery (Vetto, 2010). The causes of 
MBC are still being investigated, but awareness continues to evolve, and diagnoses have 
become much more rapid (Brain et al., 2006).  
Role of Different Factors in Breast Cancer Development 
Both biological influences and genetic (inherited) factors play a significant role in 
the development of breast cancer (Mathew et al., 2008). Certain inherited gene mutations 
might be passed from parents to their children. BRCA1 and BRCA2 are the best known 
6 
 
genes associated with breast cancer (Rossman, Libjegren, & Bergh, 2007). Most MBC 
cases can be traced back to relatives who carried BRCA2 gene mutations (Kreiter, 
Richardson, Potter, & Yasui, 2014; Mathew et al., 2008). However, Carter et al. (1998) 
reported that 54 MBC participants in their study were lacking BRCA gene mutations; two 
participants had the BRCA2 mutation not related to family, and five had BRCA2 
mutations pointing to first-degree relatives with breast cancer. Carter et al. showed that 
exposure to electromagnetic fields also might have been a contributing factor to MBC. 
Another high risk associated with MBC is hyperestrogenization resulting from 
Klinefelter’s, gonadal dysfunction, obesity, drinking alcohol, and exposure to radiation, 
whereas gynecomastia remains inconclusive (Carter et al., 1998; Fentiman et al., 2006).  
Detection of MBC 
Through tertiary means, men are detected at a later stage of breast cancer than 
women are (Robinson et al., 2008). Almost 2,000 new cases are diagnosed each year, and 
as many as 450 deaths are attributed in contrast to women with breast cancer (ACS, 
2016). Brain et al. (2006) studied the distress associated with MBC and reported that 161 
men with breast cancer who completed a questionnaire shared the same symptoms with 
women in terms of anxiety, depression, cancer-specific distress, and body image. 
Because of the gap in knowledge of MBC, I conducted this study to increase awareness 
about the predictors of mastectomy in MBC patients.  
Problem Statement 
The ACS (2016) stated that cancer places a heavy burden on the public health 
care system. Cancer comprises various categories of diseases affecting different parts of 
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the body (Fentiman et al., 2006; NCI, 2013; NIH, 2013). The incidence of MBC in the 
United States over the past 30 years has risen from 0.86% to 1.2% per 1 in 100,000 men 
and constantly continues to be discovered (Fentiman et al., 2006; Grenader, Goldberg, & 
Shavit 2008; Klein, Ji, Rea, & Stoodt, 2011; Spiers & Shaaban, 2008). MBC often results 
in mastectomy, but there has been minimal research on MBC and the predictors of 
mastectomy. I undertook this quantitative study using secondary data from 2011 to 2013 
in the Surveillance Epidemiology and End Result (SEER) database to broaden knowledge 
of the predictors of mastectomy in MBC.  
Men diagnosed with breast cancer often are in an advanced stage of the disease 
because of the lack of awareness, timely detection, and management strategies 
(Contractor, Kaur, Rodrigues, Kulkarni, & Singhal, 2008; Fentiman et al., 2006; Klein et 
al., 2011). Cancer is the second leading cause of death in men in the United States 
(Fentiman et al., 2006; Field, Campbell, & DeBoer, 2008; Hiatt & Breen, 2008; NCI, 
2013; NIH, 2013). Unlike cancer of the female breast, MBC is not yet fully understood 
(Brain et al., 2006). Knowledge and technology continue to evolve to find a cure, and 
diagnostics make it easier to discover abnormalities; however, ecological influences and 
genetic (inherited) factors play a role in the development of cancer (Brain et al., 2006). 
Most breast lumps in men usually are the result of gynecomastia, the noncancerous 
growth of breast tissue (Brain et al., 2006).  
Purpose of the Study 
The purpose of this study was to understand the influence of the predictors of age; 
race; and grade of cancer (I, II, or III) on the outcome of mastectomy in MBC. Vast 
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research has been conducted on breast cancer in general, but the majority of investigative 
work has focused on the female population, with minimal attention directed toward 
MBC. This quantitative study helps to expand knowledge of MBC, particularly the 
influence of specific predictors of mastectomy. 
Research Questions and Hypotheses  
 The analysis of secondary data required the application of theoretical 
understandings and conceptual skills to address the three RQs that guided this study: 
RQ1: How will age impact knowledge related to mastectomy in MBC? 
H01: Age will not relate to mastectomy in MBC. 
Ha1: Age will relate to mastectomy in MBC. 
RQ2: How will race account for MBC in relation to mastectomy? 
H02: Race does not account for MBC in relation to mastectomy. 
Ha2: Race does account for MBC in relation to mastectomy.  
RQ3: Is there a predictive relationship between mastectomy and Grade I, II, or III 
cancer in MBC? 
H03: There is no predictive relationship between mastectomy and Grade I, II, or 
III cancer in MBC. 
Ha3: There is predictive relationship with mastectomy and Grade I, II, or III 
cancer in MBC. 
  The RQs were analyzed using simple binary logistic regression analysis. 
Modeling included all risk factors listed above in addition to all demographic variables. 
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The independent variables (IVs) were age; race; and grade of cancer (I, II, or III). The 
dependent variable (DV) was mastectomy.  
Theoretical Framework 
Social determinants of health refer to the conditions in which people are born, 
grow, live, work, and age (World Health Organization [WHO], 2013). These social 
determinants are shaped by the distribution of money, power, and resources at global, 
national, and local levels. The social determinants framework (see Figure 1) was 
designed to aid in understanding how these factors interact with other factors in the 
causation of MBC (NCI, 2013; NIH, 2013). The framework began from the perspective 
of a disease-free state through preclinical and early cancer detection to Grades I, II, and 
III; diagnosis; survivorship; and death (NCI, 2013). Social conditions and policies, access 
to health care, social/psychological predictor factors, and the biological mechanism of 
carcinogenesis are all part of the social determinants framework (Hiatt & Breen, 2008). 
Policies and legislation pertaining health care coverage in terms of care of illness shaped 
individual behaviors and the use of clinical services regarding the early detection of 
disease (NCI, 2013). Investigators working in all areas of cancer investigation have faced 
difficulties navigating the constructs in the framework (Hiatt & Breen, 2008; NCI, 2013).  
Social determinants of health are explained to showcase improvements in the 
standard of living and sanitary reform during the 19th and 20th centuries (Scambler, 2003). 
The health of a population is closely tied to physical, social, and economic environments; 
psychophysiology and emotional states are related to physiological change and disease 
(Scambler, 2003). Understanding the causes of health is part of public health thinking; 
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Pioneers in public health recognized the importance of the social determinants in 
achieving better population health (Scambler, 2003).  
I used the social determinants of health framework to understand how social 
determinants interact with other factors to investigate MBC and to acknowledge changes 
that occur in its discovery (NCI, 2013; NIH, 2013). The framework starts with the cancer 
series and adds levels of analysis and then considers the impact of interventions in the 
management of MBC (Hiatt & Breen, 2008; NCI, 2013; NIH, 2013). The social aspects 
of the disease resulting from the complex interactions of the risk factors of economic 
support; psychosocial risks; social, environmental, and behavioral causation; genetic 
factors; and health services are implicated in more than the disease. Modification of these 




Figure 1. Social determinants of health framework. 
Adapted from WHO (2013). Social determinants of health. Retrieved from http://www.who.int/  
 
Health Care Systems 
The health care system is one social determinant of health that is responsible for 
health disparities in health status (WHO, 2013). In the social determinants of health 
framework, achieving health equity is possible “when everyone has the opportunity to 
‘attain their full health potential’ and no one is ‘disadvantaged from achieving this 
potential because of their social position or other socially determined circumstance” 
(CDC, 2012a). Access to health care has been restricted because of poverty, lack of 
education, stigma, and racism, all of which are factors contributing to health inequities 
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(CDC, 2012a). The CDC (2012a) argued that Whites have better access to the health care 
system than Blacks and members of other races do because they have health insurance.  
Access to health care. The social determinants of health framework views cancer 
from a disease-free status through the preclinical early grades (Grades I, II and III; 
survivorship; and death (NCI, 2013). Restricted access to health care, high medical costs, 
and lack of insurance coverage have led to unmet health care needs, one of which is early 
screening to prevent development of the later stages of MBC. All of these conditions 
have impacted the decision of men to receive treatment or mastectomy (Healthy People 
2020, 2016). The framework also affects social conditions and policies that can shape 
individual behaviors and the use of clinical services for early detection of disease (NCI, 
2013).  
Health inequities can be reduced in several ways: They can (a) provide programs 
for disadvantaged populations; (b) bridge the gap between underserved and better served 
populations; (c) provide access to health care in rural areas without discrimination in 
terms of gender for MBC oncology clinics (WHO, 2013); and (d) ensure equal treatment 
or care for underinsured populations, particularly MBC patients.  
Behavioral and Psychological Risk Factors 
 Psychosocial risk factors. A social network is a strong communication strategy 
in reaching communities. Social and family support systems were linked to the 
framework of this research. Psychosocial predictor variables that served as risk factors 
caused by Grade I, Grade II, or Grade III MBC led me to consider mastectomy the DV in 
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the study. The latter resulted in the following social determinant constructs of anxiety, 
depressive symptoms, distress, body image, coping mechanisms, and emotional support. 
These factors encourage healthy choices and lifestyles that are the main 
influences on the health, knowledge, behaviors, and skills that people use to cope with 
demanding life issues and circumstances (Healthy People 2020, 2016). Social support 
includes practical assistance; financial help; and the availability of information, advice, 
and psychological support (Locker, 1994). The effects of practical and emotional support 
also have been studied. According to Lyyra and Heikkinen (2006), men lacking 
emotional support were 2.5 times higher than those who had emotional support to not 
agree to undergoing mastectomy. Ostberg and Lennartson (2007) reported that 
individuals who have diverse source of support have better health outcomes.  
 Social, environmental, and behavioral causation. Social and physical 
environments, such as those that carry chemical toxins and pollutants associated with 
industrial development, influence health. Risk conditions are integral to those 
environments, and they can damage health directly. Improving environmental health 
requires political intervention and personal behavioral changes (Healthy People 2020, 
2016). Behavioral factors that can determine health status include proper nutrition, 
sufficient physical activity, and reductions in habits such as tobacco and alcohol usage 
(Locker, 1994). 
Biological and Genetic Factors 
Biological and genetic factors impact health and well-being, and they are linked 
to the health system (WHO, 2013). People whose parents have illnesses such as diabetes, 
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cancer, and high blood pressure are predisposed to also having to deal with these 
conditions. Biology plays a dominant role in the health and well-being of everyone. 
However, psychological, environmental, and cultural factors are other key areas relevant 
to any illness (Marks, Murray, Evans, & Estacio, 2011). The biological mechanisms of 
carcinogenesis, such as inheritance of the BRCA1 or BRCA2 gene, are all part of the 
social determinants framework (Healthy People 2020, 2016; Hiatt & Breen, 2008).  
Social Determinants of Health Constructs 
Constructs in the social determinants of health framework that I identified as risk 
factors in this study were the predictor variables of age; race; and grade of cancer (I, II, 
and III) in terms of health status. Age, for example, is linked to the level of social support 
that MBC patients receive (Hiatt & Breen, 2008). Sources of income also are limited for 
this age group because of the loss of work as the disease progresses (WHO, 2013). This 
period is a significant time when MBC patients need social and family support systems. 
The older that MBC patients are, the more likely it becomes that the disease will worsen. 
These situations can cause anxiety and potentially increase depressive symptoms. MBC 
patients need additional emotional support at this age to reduce distress. 
Isolation, lack of social support, low self-esteem, body image, self-blame, and 
hopelessness affect mostly younger MBC patients, whereas middle-aged patients struggle 
more to cope with and deal with the diagnosis (Ostberg & Lennartson, 2007). As 
mentioned previously, the effects of practical and emotional support have been studied. 
According to Lyyra and Heikkinen (2006), MBC patients who lacked emotional support 
were 2.5 times more likely not to have mastectomy. Ostberg and Lennartson (2007) 
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reported that individuals who had more diverse sources of support had better health 
outcomes. 
Race plays a major role in MBC. Whites, for example, are more likely to have 
more economic power than Blacks or members of other races (WHO, 2013). This 
situation makes it difficult for the latter two groups to manage the outcomes of MBC. The 
social determinants of health are shaped by the distribution of money, power, and 
resources at the global, national, and local levels. The unequal balance of this distribution 
has an impact on health disparities, the unfair and avoidable differences in health status 
seen within and between countries (WHO, 2013).  
Recent studies on social support and health have focused on the relationship 
between social support and well-being. Individuals who are single, widowed, or divorced 
have increased cancer mortality rates when compared to married or partnered individuals. 
Jingzhi and Lambert (2007) studied women and men with breast cancer and found that 
single men had a mortality rate of 1.96% in comparison to widowed men at 2.64% and 
divorced men at 3.39%. The differences were much larger for men than for women with 
breast cancer. Research has shown that social support predicts the survival rates of 
patients with breast cancer (Kroenke, Kubzansky, Schernhammer, Holmes, & Kawachi, 
2006).  
Nature of the Study 
I conducted this quantitative study using archival SEER data from 2011 to 2013. 
The analysis required the same basic research principles and steps as studies using 
primary data. This paper contributes to the discussion of secondary data analysis as a 
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research method for MBC and psychosocial information in a study of MBC in the United 
States.  
Secondary Data Analysis  
Johnston (2014) defined secondary analysis as “any further analysis of an existing 
dataset which presents interpretations, conclusions or knowledge, either adding towards 
the original investigator or a little different from those presented in the first reported 
results” (p. 620). Most research begins with the desire to learn what has been studied and 
what remains to be learned about a topic (Katsirikou, 2013). Secondary data analysis 
takes this step further by reviewing and analyzing previously collected data on the topic 
of interest (Katsirikou, 2013). Although secondary data analysis is flexible and can be 
used in several ways, it also an experiential exercise with procedural and evaluative 
phases, just as when collecting and evaluating primary data (Doolan & Froelicher, 2008). 
Secondary data analysis remains an underused research technique in many fields, 
including breast cancer.  
Process of Secondary Analysis  
When conducting research, the topic of interest and the RQs determine the ways 
in which the researcher collects, analyzes, and interprets the data (Creswell, 2009). I 
conducted this study using a quantitative research design that began with the 
development of the RQs, identification of the data set, and thorough evaluation of the 
data set. Ethical issues regarding this study were addressed by the original investigators, 
who also ensured that all protocols had been explained and consent forms signed. The 
objective of my study was to collect archival data on age; race; and grade of cancer (I, II, 
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or III) from the SEER database to determine their relationship to men’s willingness to 
undergo mastectomy.  
Definitions of Terms 
Adjuvant therapy: The use of another form of treatment such as chemotherapy or 
radiation in addition to surgery (NCI, 2013). 
Body image: The feelings and perceptions that individuals have about their bodies 
(Brain et al., 2006). 
Breast cancer: An abnormal formation of breast tissue that has grown and 
infiltrated the surrounding healthy tissue of the breast (NIH, 2013). 
Depression: Negative thoughts, emotions, or feelings of hopelessness that lead to 
not wanting to perform normal activities (Brain et al., 2006). 
In situ: The original, natural, or existing place or position (NCI, 2013). 
Mastectomy: The elimination of breast tissue (NIH, 2013).  
Metastatic disease: Manifestation of malignancy as a second growth arising from 
the primary growth but in a new location; can be spread by lymphatic system, blood, or 
bone marrow (CDC, 2013). 
Perception: A personal representation of reality or experience (Larson, 2009; 
WHO, 2013) 
Staging: A method of classifying cancer according to the full extent of the disease 
in the body. It helps in determining appropriate treatment and estimating the chances of 




I made the following assumptions when conducting this study: 
• The MBC secondary data in the SEER database were adequate to reach the 
number needed for the study. 
• The MBC secondary data in the SEER database were valid.  
• Informed consent was signed by participants in the study conducted by the 
original investigators. 
• My being a female investigator working with the NCI SEER and Behavioral 
Risk Factor Surveillance System (BRFSS) registrar on a daily basis would not 
affect any of the organization’s willingness to provide me with the secondary 
data in a timely manner.  
Scope and Delimitations 
The scope of this study was limited to U.S. archival data because of the cost. The 
study was limited to men 18 years of age and older because of the small target population 
of men in the United States who have had breast cancer. The sample size was limited by 
the scant published data in United States available for retrieval to investigate the 
associative risk factors relating to MBC, namely, the psychosocial variables of age, race; 
and grade of cancer (I, II, or III) to the outcome of mastectomy in the United States.  
As a social change implication, the scope of the study covered only data for men 
who had not yet had received a recommended yearly mammogram screening. According 
to the ACS (2011), men are yet to be included in the guidelines for baseline mammogram 
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for women at age 40. Because the data were archival, there was no opportunity to contact 
any of the men who were in the initial study.  
Limitations 
One limitation of the study was that no previous researchers had specifically 
focused on grading MBC. Looking for archival data took SEER personnel months to 
finish. In addition, SEER personnel raised numerous objections and tried to discourage 
the retrieval of the required archival data. Another limitation was the fact that the data 
had been collected by other researchers, which meant no contact with the participants, no 
follow-up questions, and no confirmation of the appropriateness of the original 
procedures.  
Significance 
MBC has been diagnosed in one of every 1,000 men in the U.S. population (ACS, 
2016; Fentiman et al., 2006; NCI, 2016a; NIH, 2013). The CDC (2012a) and Doornbos, 
Zandee, DeGroot, and De Maagd-Rodriguez (2013) stated that many men with MBC 
have yet to be diagnosed and treated. Therefore, the goal of this study was to support 
positive social change in helping men to accept that they also can become the victims of 
breast cancer and that they can receive the same timely treatment as women. This study 
was significant for being the first study of MBC investigating the impact of the variables 
of age; race; and grade of cancer (I, II, or III) on mastectomy outcome. Other researchers 
have studied the stages of cancer, but not the grades of cancer. 
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Implications for Social Change 
Public health has many disciplines whose core principles are to improve 
population health and well-being (Walden, 2014). The significance of this study is to 
eliminate hindrances and the lack of information. There has been little research on the 
emergence and prevention of MBC. Public knowledge might lead to more awareness and 
use of mastectomy by patients at either Stage II or Stage III of MBC. 
Screening and daily life changes are vital to early detection (CDC, 2012a). 
Clinical professionals need to be well informed about of the reasons for not including 
men in their dissemination of information about breast cancer. I hope that the results of 
this study will help to eliminate the risk of MBC by educating the population. One goal 
of this study was to eradicate the stereotyping of breast cancer as a female disease. The 
ongoing emergence of medical technology and continued education to benefit the public 
will help to ensure greater health awareness at the individual, community, and global 
levels. Disparities in breast cancer mortality among men are apparent. Results will add to 
the current knowledge base by informing the public, clinical professionals, and patients 
about the relationship between the predictors of age; race; and grade of cancer (I, II, or 
III) on the outcome of mastectomy in MBC.  
Summary 
Chapter 1 introduced the problem, nature of the study, significance of the study, 
and the RQs. Also included was information about the assumptions, scope and 
delimitations, and the limitations of the study. In Chapter 2, I present the literature 
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Chapter 2: Literature Review 
Introduction 
MBC occurs infrequently, and there has been a gap in knowledge about the 
disease because of limited research and inadequate funding inside and outside of the 
United States (Chavez-MacGregor et al., 2013; Kornegoor et al., 2012). The incidence of 
MBC is increasing globally. The purpose of this study was to understand the influence of 
the predictors of age; race; and grade of cancer (I, II, or III) on the outcome of 
mastectomy in MBC.  
Literature Review Strategy 
I searched the Medline and ProQuest databases to obtain relevant literature on the 
topic of MBC. The key search terms under the medical subject heading MeSh were 
breast in men; cancer; Grades I, II & III; male; social support; altered body image; 
coping with breast cancer; depressive symptoms; breast cancer; and family support. The 
search for relevant literature spanned 2001 to 2014, but the archival data used in the study 
were from 2011 to 2013. 
Rationale for the Study 
The purpose of this study was to understand the influence of the predictors of age; 
race; and grade of cancer (I, II, or III) on the outcome of mastectomy in MBC. This 
quantitative investigation focused on archival data from 2011 to 2013 obtained from the 
SEER database. The data were for men 18 years of age and older who had been 
diagnosed with breast cancer and who considered mastectomy as part of treatment. Only 
a few studies have sought to identify the influence of the variables of age, race, and grade 
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of cancer in relation to mastectomy in men, making this study even more important in 
filling the gap in the research.  
Social Predictors of MBC 
Age; race; and grade of cancer (I, II and III) were the IVs determining 
mastectomy for patients with MBC. Brain et al. (2006) reported a prevalence of 
psychosocial variables in 161 men using a cross-sectional questionnaire to determine 
whether age of diagnosis resulted in mastectomy. The questionnaire contained the 
variables of anxiety, depressive symptoms, cancer-specific distress, body image, and 
coping and support needs, as well as demographic variables (Brain et al., 2006). Results 
indicated that anxiety was not reported because depressive symptoms associated with 
altered body image was at 35% of the variance (p < .001). The clinical level of the 
anxiety reported was 6%, while 23% of those reported a rise in cancer-specific distress 
(Brain et al., 2006). Body image, avoidance of coping, and emotional support was at 51% 
(p < .001; Brain et al., 2006). Brain et al. stated that the largest impediment to 
accommodating the disease was the inability to cope with the disease, the altered body 
image, and the lack of support needs. Brain et al. concluded that age affected MBC 
patients in terms of their body image and psychological needs. 
Merletti, Galassi, and Spadea (2009) asserted that timely access to health care is 
essential to diagnose and treat breast cancer, and reduce the mortality and morbidity 
rates, adding to the gap identified in Chapter 1 (Burson et al., 2009; Munn, 2001; Rachid 
et al., 2009). Breast cancer is 100 times more prevalent in women than in men, and even 
though most cases of MBC are diagnosed in men between the ages of 60 and 70 years, 
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men of any age can become MBC patients (Rachid et al., 2009). Several researchers (e.g., 
Brain et al., 2006; Burson et al., 2009; Hiatt & Breen, 2008; Robinson et al., 2008; 
Rosenbaum et al., 2004) have stated that among unmarried men, anxiety, depressive 
symptoms, altered body image, and the lack of coping mechanisms and emotional 
support have an impact on their self-esteem, with altered body image having the greatest 
impact. Among married men, distress has been related to decreased satisfaction in terms 
of intimacy in the relationship, lowered sexual function, and less appreciation of spouse 
or partner (Brain et al., 2006). Additional problems encountered among older men 
include decreased physiological arousal, decreased sexual arousal, decreased interest in 
sexual attractiveness, and no hope of achieving orgasm (Brain et al., 2006).  
MBC accounts for only 1% of all breast cancers (NCI, 2016a). Researchers have 
reported on the evaluation, treatment, and results of male patients with MBC (Ahmed et 
al., 2012; Gómez-Raposo, Tévar, Moyano, López Gómez, & Casado, 2010). Male 
patients with a histological diagnosis of breast cancer from 2001 to 2010 who had been 
evaluated previously (Ahmed et al., 2012; Fentiman et al., 2006; NCI, 2013; NIH, 2013) 
have been given the recommendation to undergo modified radical mastectomy as a 
treatment option.  
A diagnosis of DCIS among men is rare because of the lack of screening detection 
methods, so MBC usually presents as a profound mass (Doyle et al., 2011 Fentiman et 
al., 2006; NCI, 2013; NIH, 2013). Typically, MBC presents with a unilateral, painless, 
subareolar mass that often is located away from the nipple (Doyle et al., 2011; Fentiman 
et al., 2006; NCI, 2013; NIH, 2013). Twenty-nine percent of MBC patients with invasive 
25 
 
ductal cancer have surgery; 17% have surgery for tumors, particularly unadulterated 
DCIS (Vetto, 2010).  
Researchers have found that MBC cases are much more common in relatives with 
the BRCA2 gene than in those with the BRCA1 gene (Fentiman et al., 2006; Mathew et 
al., 2008; NCI, 2013; NIH, 2013). Fentiman et al. (2006) studied 54 participants with 
MBC who lacked BRCA1 mutations, but a BRCA2 transfiguration was found in two 
participants. The same researchers confirmed that five patients had BRCA2 mutations 
inherited from first-degree relatives with breast cancer.  
Work-related risks associated with a diagnosis of MBC include environments 
with elevated temperatures and exhaust fumes; however, electromagnetic fields have not 
yet been implicated (Gómez-Raposo et al., 2010). Patients who have experienced 
hyperestrogenization resulting from Klinefelter’s, gonadal dysfunction, obesity, and high 
alcohol consumption, along with exposure to radiation, have an increased risk of 
developing MBC (Fentiman et al., 2006; Gómez-Raposo et al., 2010). Nipple inversion 
usually presents when a lump is discovered, but in 40% of men, this discovery often does 
not come until Stage III or Stage IV of the disease. Most MBC tumors are ductal; 10% 
are DCIS. Surgery performed on patients with this condition usually involves 
mastectomy with axillary clearance or sentinel node biopsy. The decision to undergo 
radiotherapy is indicated by the stage of MBC and is similar to female breast cancer 
(Fentiman et al., 2006; Gómez-Raposo et al., 2010). Hormone therapy is the core 
treatment for metastatic disease, according to Fentiman et al. (2006), but 
chemotherapeutic agents also can be used to provide palliation. There is a need for 
26 
 
national initiatives to improve information about and support for treatment of MBC. This 
study will aid in filling the gap.  
Theoretical Foundation 
Much research has been conducted on cancer in general, but the majority of 
studies have focused primarily on female breast cancer and have excluded MBC. The 
purpose of this study was to understand the influence of the predictors of age; race; and 
grade of cancer (I, II, or III) on the outcome of mastectomy in MBC. The social 
determinants of health play an essential role in enhancing the psychological well-being of 
these patients in terms of social support. 
Ruddy and Winer (2013) stated that more research is needed to explore the 
relationship between coping strategies and emotions experienced by individuals dealing 
with MBC. Brain et al. (2006) stressed that further study will help to capture information 
relevant to the pattern of anxiety, depressive symptoms, distress, body image issues, 
coping mechanisms, and emotional support from initial diagnosis through various 
treatment regimens. 
Conceptual Framework 
The study was guided by the social determinants of health framework, which was 
designed to aid in conceptualizing how social determinants and sociological factors 
interact with other factors in the etiology of MBC and to realize changes over time. The 
framework begins with the cancer series, added levels of analysis, and considered the 
impact of interventions in the management of MBC (Hiatt & Breen, 2008). As mentioned 
in Chapter 1, the social determinants of health are the conditions relevant to how people 
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grow, live, work, and age. These conditions are impacted by the distribution of money, 
power, and resources at the global, national, and local levels. Following are details about 
the constructs in the social determinants of health framework.  
Social Support 
Social support, one construct in the social determinants of health framework and 
the main construct of this study, was defined by Rab (2012) as “availability of support 
which refers to the degree to which interpersonal relationships serve a particular 
function” (p. 2). Social support is an important predictor in the ability of individuals to 
cope with difficult circumstance and adjust to psychological and social demands. Several 
studies, according to Rab, have indicated that men’s perceptions of close supportive 
relationships with their spouses and close friends are positively correlated with their 
ability to cope with MBC. 
Age 
Age is a sociological predicator variable. As a construct in the social determinants 
of health framework, age determines how well MBC patients handle anxiety in terms of 
worry and fear whenever the symptoms become more severe or when undergoing testing 
to determine whether the cancer has progressed (Rab, 2012). Some of the most common 
fears are painful procedures associated with the disease and side effects such as hair loss, 
nausea, fatigue, and pain (Rab, 2012). MBC patients worry about disruptions to their 
daily lives that can lead to fear and anxiety because of their inability to work. Older MBC 
patients who have already reached retirement worry less.  
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The factors predicting anxiety include personal history of depression, personal 
history of anxiety, painful treatment protocols, and difficulty controlling bladder during 
therapy (Brain et al., 2006, Rab, 2012). This last factor is of particular relevance to men 
age 65 years and older. During remission, MBC patients are required to have follow-up 
visits with their oncologists to manage MBC. Anxiety and worry intensify at this stage 
because of the fear of negative updates.  
Race  
Race is another construct in the social determinants of health framework. Racial 
disparities exist in the management of MBC in terms early diagnosis and access to health 
care. Whites, more so than Blacks, are mostly insured (WHO, 2013). Blacks are 
underinsured because of the lack of social support, poor employment prospects, and lack 
of resources. Having insufficient resources can cause distress that manifests as 
depression, anxiety, insomnia, anorexia, poor concentration, and the inability to function 
in daily chores.  
Cancer Grade I 
Adding to the social determinants of health framework, the grade of cancer refers 
to the aggressiveness of its management. Grade I is a low grade; in Grade II, cells 
become differentiated and require treatment; and in Grade III, the cells grow and spread 
rapidly (NCI, 2013). MBC patients at this latter stage have an inability to cope, and they 
can experience frustration and emotional distress. Grade I denial in breast cancer leads to 
deregulation of the immune system and results in long-term physical and emotional 
29 
 
problems that cause distress. Many patients with Grade 1 cancer who are waiting for 
MBC test results experience tremendous distress. 
Cancer Grade II 
 Grade II is another construct of the social determinants of health framework. 
MBC patients who seek a mastectomy during Grade II should report body image issues to 
their partners or caregivers to seek emotional help in order to deal with the disease (Rab, 
2012). Caregivers or partners might offer advice regarding the treatment to follow in 
terms of breast-conserving surgery, or reconstructive surgery, to enhance body image 
(Rab, 2012). 
Cancer Grade III 
 Grade III is another construct in the social determinants of health framework. 
Patients with this grade of cancer need help coping with the effects of chemotherapy on 
MBC (NCI, 2013). MBC patients report very poor physical and emotional qualities of 
life when coping with the treatment regimen. The side effects of antiestrogen during 
treatment can lead to weight gain, fatigue, and depression (Rudy & Winer, 2013). 
Because of the side effects of treatment at any stage of cancer, men with MBC need 
emotional support (Brain et al., 2006). 
Psychosocial comorbidities also can have a negative effect on MBC patients’ 
emotions (Brain et al., 2006). Feelings of uncertainty give rise to feelings of 
hopelessness. The absence of social networks can lead to decreased survival rates and 




Nursing staff, paramedics, ancillary staff, and social support staff have a role in 
alleviating the symptoms and managing the welfare of MBC patients in terms of 
chemotherapy and pain management. This role can result in a positive relationship with 
MBC patients. The social determinants of health framework offered a sound theoretical 
foundation for this study. The purpose of this study was to understand the influence of the 
predictors of age; race; and grade of cancer (I, II, or III) on the outcome of mastectomy in 
MBC. 
Epidemiology 
The yearly report incidence of MBC in Europe is one in 100,000, and less than 
1% of all breast cancer patients are men, statistics that are similar to those in the United 
States (Fentiman et al., 2006). According to Weiss, Moysich, and Swede (2005), the 
epidemiology of MBC resembles that of female breast cancer. Major genetic factors 
connected with an increased risk of breast cancer for men include BRCA2 mutations, 
which are believed to account for most cases of inherited breast cancer (Weiss et al., 
2005). Klinefelter’s syndrome is another risk factor, as is a positive family BRCA I or II 
history (Weiss et al., 2005). Alleged genetic factors include AR gene mutations, CYP17 
polymorphism, Cowden syndrome, and CHEK2 (Weiss et al., 2005).  
Epidemiologic risk factors for MBC include disorders relating to hormonal 
imbalances such as obesity and testicular disorders (e.g., cryptorchidism, mumps orchitis, 
and orchiectomy), as well radiation exposure (Peschos, 2008). Other epidemiologic risk 
factors include prostate cancer as a secondary causation, prostate cancer treatment, 
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gynecomastia, and occupational exposure (Peschos, 2008), such as working in areas that 
contain polycyclic aromatic hydrocarbons, electromagnetic fields, or high temperatures. 
Another factor is dietary intake. Suggested examples could be “meat intake, fruit, and 
vegetable consumption, and alcohol intake” (Weiss et al., 2005, p. 2).  
Race 
Race accounts for the increased risk of developing a type of cancer that is 
genetically inclined or inherited. For example, the triple negative breast cancer gene was 
seen mostly in men of Black ancestry having receptors for estrogen and progesterone. 
This Black ancestry origin inhibits the response to medications that block estrogen 
production, making chemotherapy the treatment of choice for this group of men (ACS, 
2011). Ashkenazi Jewish men have a higher risk than men from other ethnic groups of 
carrying the BRCA gene. According to Chavez-MacGregor et al. (2013), White men 
have of the highest incidence of breast cancer, followed by Blacks and Hispanic 
Americans. They also found that Black men are more likely to die from MBC because of 
the advanced stage of the disease at diagnosis.  
  Pavinato (2008) conducted a retrospective study of 146 men who were diagnosed 
with MBC between 1990 and 2007. Results showed that by the time the men found out 
that they had breast cancer, it was already at a later stage and had spread to the lymph 
nodes and then had metastasized to other organs. Reynolds (2007) analyzed race and 
other “predictors of treatment and survival among 510 men over 65 yrs. diagnosed with 
stage I-III breast cancer between 1991 and 2002” (p. 1), noting that in regard to 5-year 
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survival rates, approximately 456 (90%) of survivors were White men, and 34 (6.6%) 
were Black men.  
Ethnic Factors 
Sandhu et al. (2012) stated that African and Ashkenazi Jewish heritages have 
been associated with an increased risk of MBC. Sandhu et al. remarked that MBC 
accounted for between 7% and 14% of all breast cancers in sub-Saharan Africa at the 
time of the study. Black men have the highest occurrence in the United States (Sandhu et 
al., 2012). Specific factors responsible for the increased incidence in these ethnic groups 
are not known. The increased risk in Ashkenazi Jewish populations is the result of a high 
prevalence of BRCA mutations, also known as founder mutations, that are specific to that 
population (Sandhu et al., 2012). Ethnicity was not a factor in my study because of the 
limited number of men diagnosed with MBC.  
Age 
MBC is usually diagnosed at an older age than cancer is diagnosed in women. 
Men who are diagnosed often are not treated because of the advanced spread of the 
disease. The standard age for men at diagnosis is > 65 years (Chavez-MacGregor et al., 
2013). However, the current study was limited to men 18 years of age and older. Table 1 
shows the age-adjusted SEER incidence rates by year and race for MBC (NCI, 2014) in 
nine areas of the country (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New 
Mexico, Seattle, Utah, and Atlanta). Rates were per 100,000 and were age-adjusted based 






Age-Adjusted SEER Incidence Rates by Year and Race 
Year of diagnosis Other  White Black 
2000 1.16 1.14 2.86 
2001 1.22 1.22 1.66 
2002 1.15 1.13 1.95 
2003 1.33 1.34 1.85 
2004 1.21 1.23 1.61 
2005 1.06 1.15 0 
2006 1.16 1.19 1.54 
2007 1.11 1.14 1.82 
2008 1.18 1.2 1.43 
2009 1.19 1.25 0 
2010 1.24 1.13 2.93 
2011 1.42 1.37 2.74 
2012 1.35 1.34 2.1 
 
Gender 
  Although breast cancer cases are usually diagnosed in women, men make up 1% 
of breast cancer cases (ACS, 2011). In fact, the rates for women and men as well as 
different ethnicity groups and age groups in the United States vary. However, because my 
study focused on men only, so gender was not an issue. 
Mortality Rate in United States 
An estimated new cases of female breast cancer in the United States are 249,260 
reported in 2016 and only 2,600 new cases of MBC (NCI, 2016a). In the United States, 
440 men were estimated to die from the disease. Table 2 shows invasive MBC incidence 






Invasive MBC Incidence Rates in Six Major U.S. States 2008-2012  
Region Population at risk cases Crude rate Age-adjusted rate 95% CI 
Pennsylvania 30,951,263 567 1.83 1.64 [1.50, 1.78] 
Florida 46,172,326 885 1.92 1.58 [1.48, 1.69] 
New York 46,968,042 707 1.51 1.50 [1.39, 1.62] 
Illinois 31,450,263 400 1.27 1.34 [1.21, 1.48] 
California 92,764,862 953 1.03 1.16 [1.08, 1.24] 
Texas 62,557,960 568 0.91 1.10 [1.01, 1.20] 
Combined 310,864,716 4,080 1.31 1.35 [1.31, 1.39] 
 
Global Rates of MBC 
In England, 300 men and 41,000 women are diagnosed with breast cancer 
annually (NCI, 2014). Even though most of prevention campaigns are aimed at women 
rather than men, research carried out at Texas University indicated that MBC cases are 
rising and that most of the men are detecting it at a very late stage. The study stated that 
male cases increased from 0.86 to 1.08 per 100,000 men in 20 years (“Male Breast 
Cancer Numbers Rising Most Fail to Spot It Until It Has Spread to Lymph Nodes,” 
2004). The percentage globally is higher, with breast cancer being diagnosed in Zambia 
at a rate of 15% and 6% in Egypt and Tanzania (“Male Breast Cancer Numbers Rising 
Most Fail to Spot It Until It Has Spread to Lymph Nodes,” 2004). 
Grading 
Grade of MBC is a rating that tells physicians how the cancer is behaving 
microscopically. Looking into a microscope, one can see that MBC cells are 
differentiated into an alarming appearance and pattern that is unlike normal cells. There 
also are other ways of determining the grade of MBC. Two grading and scoring systems 
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are the Nottingham Histologic Score System and the Elston-Ellis Modification of Scarff-
Bloom-Richardson Grading System. Using these systems, pathologists take into account 
three factors: (a) gland formation number, or differentiation, meaning how well it will 
replicate a normal cell; (b) pleomorphism, or nuclear features, meaning how bad the cell 
looks under a microscope; and (c) mitotic pattern or division activity, meaning creating 
family. 
Histologic Grade and Score 
To determine glandular (acinar)/tubular differentiation, the following rating 
system is used: 
Score 1: indicates tumor > 75% forming glandular/tubular structures. 
Score 2: indicates tumor is 10% to 75% forming glandular/tubular structures 
Score 3: indicates when tumor is < 10% and is forming glandular/tubular 
structures. 
  To grade nuclear pleomorphism of MBC, the following scoring system is used:  
Score 1: Small nuclei with a slightly increase in size in comparison to normal 
male breast epithelial cells will be visible under a microscope, Uniform nuclear 
chromatin appears regular and uniform, and has slight variations in size. 
Score 2: Under a microscope, these cells appear usually larger than normal cells, 
with nucleoli medium in size and shape. 
Score 3: During this stage, the cells exhibit remarkable enlarged size with 




Mitotic Characteristics of MBC Grade 
This technique requires use of a high-definition microscope. BC cells are 
manually counted on a slide to see the mitotic ability on a 10X high power fields using a 
high power field 0.55 mm condenser. Following is the scoring system: 
Score 1: ≤ 7 mitoses MBC cells per 10X high-power fields. 
Score 2: 8 to 14 mitoses MBC cells per 10X high-power fields. 
Score 3: ≥ 15 mitoses MBC cells per 10X high-power fields. Once the pathologist 
looks at all of the cells, then an overall grade is determined as Grade 1, Grade II, or 
Grade III cancer. Grade 1 tumors have a score of 3 to 5, Grade 2 tumors have a score of 6 
or 7, and Grade 3 tumors have a score of 8 or 9. 
Staging 
The NCI (2014) accepted the following tests to define the extent of cancer in the 
body: 
• Radionuclide: This is a radioactive substance that uses a blue dye injected 
near the tumor that flows through the lymph ducts to the nodes. The first 
lymph node to receive the dye is extracted and viewed under the microscope 
for cancer cells (Macmillan Cancer Support, 2013; NCI, 2014). 
• CT scan (CAT scan): This is a scan that contains dye contrast that takes a 
series of pictures of the affected area inside the body from different views 
(Macmillan Cancer Support, 2013; NCI, 2014). 
• Bone scan: A bone scan usually is done to check for rapidly dividing cancer 
cells. It is performed by injecting a radioactive material into the vein that 
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travels through the bloodstream to lodge in the bone. It is detected by the 
scanner (Macmillan Cancer Support, 2013; NCI, 2014). 
• Positron Emission Tomography Scan (PET): This scan is used to find 
malignant or tumor cells in the body. It is done by injecting a radioactive 
glucose sugar into the vein; the PET scanner rotates around the body, taking 
pictures of cells aided by illumination of glucose that helps the cancer cells to 
appear brighter on the cancer cells, which occurs because cancer cells take up 
more glucose than normal cells do. (NCI, 2014) 
The medium allows oncologists to detect the stage of breast cancer in order to 
describe the size of the tumor and determine whether it has spread to other organs 
(Macmillan Cancer Support, 2013; NCI, 2014). The initial step in assessing a suspicious 
breast lump in a man is to perform a mammogram (Fentiman et al., 2006; Giordano, 
2005). The sensitivity and specificity rates of a mammogram to diagnose MBC are about 
92% and 90%, respectively (Fentiman et al., 2006; Giordano, 2005; Gómez-Raposo et al., 
2010). Usually, a mammogram can differentiate between a malignancy and 
gynecomastia. The radiological features indicative of malignancy include, but are not 
limited to, proximity away from the nipple, spiculated margins, and microcalcifications 
that are less common in men than in women who have breast cancer (Fentiman et al., 
2006; Giordano, 2005; Gómez-Raposo et al., 2010). 
Risk Factors 
 Gómez-Raposo et al. (2010) conducted a prospective study using NIH-AARP 
Diet, a health study of 324,920 men, of which 121 developed breast cancer. A notable 
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risk was seen in the men who had first-degree relatives with breast cancer (RR 1.92), a 
history of bone fracture after age 45 (RR 2.2), obesity (RR.1.79), and decreased levels of 
physical activity (Gómez-Raposo et al., 2010). Most of the men in the study had no 
identifiable risk factors; however, several risk factors had been identified in their study, 
including genetics (BRCA1, BRCA2 mutations); Klinefelter’s syndrome, ethnic factors, 
family history of breast cancer, and Ashkenazi Jewish heritage. Endocrine risks included 
estrogen excess, which has to do with liver disease; exogenous estrogens; lifestyle; and 
environmental and occupational exposure (Gómez-Raposo et al., 2010). 
Klinefelter’s syndrome is the worst threat for emergent MBC that occurs in 
approximately one in 1,000 men (Fentiman et al., 2006; Giordano, 2005; Gómez-Raposo 
et al., 2010). “Klinefelter’s syndrome is characterized by the addition of at least one X 
chromosome to the normal XY karyotype which is usually 47XXY” (Gómez-Raposo et 
al., 2010, p. 451). It is characterized by enlarged testes, gynecomastia, high serum 
gonadotropins, and low serum testosterone levels (Fentiman et al., 2006; Giordano, 2005; 
Gómez-Raposo et al., 2010).  
Ruddy and Winer (2013) conducted a systematic review of literature relevant to 
MBC risk factors, biological characteristics, presentation, prognosis, treatment, and 
survivorship between 1987 and 2012 and included 20 patients. Results showed that a 
BRCA2 mutation, age, conditions, estrogen/androgen ratio, and radiation were proven 
risk factors. Ruddy and Winer concluded that even though the disease biology is very 
distinct in men, the diagnostic approaches and treatment protocols for men are generally 
extrapolated from those used with women who have cancer. Reasons include inadequate 
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research with male participants and that survivorship might include sexual and hormonal 
side effects of endocrine therapies as well as the psychosocial impact of breast cancer.  
The risk of breast cancer in genetically affected individuals is 20 to 50 times 
higher than in 46XY men (Gómez-Raposo et al., 2010). The risk increases with inherited 
BRCA2 rather than BRCA1 mutations (Fentiman et al., 2006; Giordano, 2005; Gómez-
Raposo et al., 2010). An example would be the genetically susceptible mother in a family 
who has been diagnosed with breast cancer. If she had given birth to only male children, 
then the chances of one of them inheriting the BRCA2 gene would be great (Gómez-
Raposo et al., 2010). Testicular conditions are another risk factor associated with MBC. 
They include enlarged or undescended testes, congenital inguinal hernia, orchiectomy, 
orchitis, and infertility (Fentiman et al., 2006; Giordano, 2005; Gómez-Raposo et al., 
2010). 
Diagnosis 
MBC usually presents as a palpable mass with a unilateral, painless subareolar 
mass that often is located away from the nipple (Doyle et al., 2011; Fentiman et al., 2006; 
NIH, 2013). MBC is different from gynecomastia, which often is painful, and although 
frequently asymmetrical or unilateral, it is subareolar and central in position (Doyle et al., 
2011; Fentiman et al., 2006; NIH, 2013). Ultrasound can be an effective diagnostic tool 
to identify possible node attachment in male patients. MBC on an ultrasound image can 
be invasive and can typically appear as a solid lesion that requires a biopsy (Fentiman et 
al., 2006; Giordano, 2005; Gómez-Raposo et al., 2010) to confirm the diagnosis. 
Estrogen receptor, progesterone receptor, and Her2-neu status should be assessed in male 
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patients (Fentiman et al., 2006; Giordano, 2005; Gómez-Raposo et al., 2010). A core 
biopsy is chosen for later stages of cancer so that a definitive diagnosis can be made 
(Fentiman et al., 2006; Giordano, 2005; Gómez-Raposo et al., 2010). 
The diagnostic assessment and staging systems for MBC patients are the same as 
for women with breast cancer (Fentiman et al., 2006; Giordano, 2005). The scope of the 
cancer is recognized by laboratory tests, radiography, and bone and CT scans (Fentiman 
et al., 2006; Giordano, 2005; Gómez-Raposo et al., 2010). The tumor stage is determined 
using the American Joint Committee on Cancer’s classification system, which considers 
tumor size, nodal involvement, and distant metastases (as cited in Gómez-Raposo et al., 
2010). Only 48% of MBC cases are diagnosed at Stage I or Stage II; most men tend to be 
diagnosed at later stages of the disease (Fentiman et al., 2006; Giordano, 2005; Gómez-
Raposo et al., 2010). 
Prognosis 
The most significant prognostic pointers are stage of cancer at diagnosis and 
position of the lymph node (Fentiman et al., 2006). The normal estimated survivor rate 
for MBC in comparison to other breast cancers is about 40% to 65%, with a 5-year 
average, but when clustered by appearance in MBC, the 5-year survival rate is 75% to 
100% for a Grade I diagnosis. The percentage decreases to 50% to 80% for a Grade II 
diagnosis and then declines even further to 30% to 60% for a Grade III diagnosis (Fazel 




Grade of MBC is a rating that tells physicians how the cancer is behaving 
microscopically. Looking into a microscope, one can see that MBC cells are 
differentiated into an alarming appearance and pattern unlike normal cells. A laboratory 
scientist with oncology experience rates the cancer on a scale ranging from 1 to 3 
pending pathology confirmation. When the grade is at the tumor level, the cells look 
different from normal cells. A low-grade breast cancer grows at a slower rate than a 
Grade II or a Grade III cancer, both of which are high-dividing cells that are likely to 
spread rapidly and are indicative of a poor prognosis and a poor survival rate because of 
their resistance to chemotherapy and radiation (NCI, 2012). 
MBC Grade and Treatments 
  MBC treatment oncologists take into account the tumor grade and other critical 
factors such as the stage of MBC, age of the patient with MBC, and the patient’s overall 
health. This is the first step in determining the most appropriate regimen for the MBC 
client after grading and staging (NCI, 2012). 
Treatment of Early Stage I and Stage II Breast Cancer 
Management of localized, invasive early MBC follows the same general treatment 
protocols as for female breast cancer (Fentiman et al., 2006; Giordano, 2005; Gómez-
Raposo et al., 2010). The treatments, according to Omene and Tiersten (2010), are 
customary modified radical mastectomy with axillary lymph node dissection, as well as 
lymph node biopsy. Breast-conserving therapy is not an option for men with early Stage I 
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and Stage II MBC because men lack breast tissue; however, it remains an option for 
women (Fentiman et al., 2006; Giordano, 2005; Gómez-Raposo et al., 2010). 
Another treatment for early Stage I and Stage II of MBC is adjuvant radiotherapy. 
Men tend to be treated less often than women for postmastectomy radiation because they 
usually have more nipple or skin involvement. The deciding factor in selecting adjuvant 
therapy is when men have positive lymph nodes or tumors larger than 2 inches (Gómez-
Raposo et al., 2010). 
An additional treatment for early Stage I and Stage II of MBC is adjuvant 
hormonal therapy. Tamoxifen in MBC is frequently used because of the reduced risk 
associated with reappearance and death. Adjuvant tamoxifen is traditionally used in 
patients with Stage II and Stage III cancer (Gómez-Raposo et al., 2010). Adjuvant 
chemotherapy such as cyclophosphamide, methotrexate, and fluorouracil also is widely 
used in MBC. These choices are based on performance benefits from the perspective of 
clinical trials; a 5-year survival rate has been noted in some studies at > 80% significance 
(Fentiman et al., 2006; Giordano, 2005; Gómez-Raposo et al., 2010). It is recommended 
for men with an intermediate or a high risk of primary breast cancer (Fentiman et al., 
2006; Giordano, 2005; Gómez-Raposo et al., 2010). 
Treatment of Stage III or Stage IV Cancer 
Men who have Stage III or Stage IV breast cancer (Gómez-Raposo et al., 2010; 
Leong, 2005) undergo treatment that is similar to that for women. Chemotherapy is 
usually started initially, and surgery might be an option if tumors can be removed 
surgically (Fentiman et al., 2006; Giordano, 2005). Patients usually are given radiation 
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therapy and adjuvant tamoxifen for HR-positive disease after mastectomy (Fentiman et 
al., 2006; Giordano, 2005; Gómez-Raposo et al., 2010). Induction hormone therapy 
represents an interesting option for most patients and is preferred to chemotherapy 
(Fentiman et al., 2006; Giordano, 2005; Gómez-Raposo et al., 2010; Sousa, Moser, & 
Cardoso, 2013). Gómez-Raposo et al. (2010) reported that 24 male participants in their 
study who had Stage II breast cancer were treated at the NCI with adjuvant 
cyclophosphamide, methotrexate, and fluorouracil.  
Surgery 
Fields, Devitt, Fisher, and Rabinovitch (2013) sought to determine the stage-
specific management of MBC using either surgery or radiation. A total of 4,276 cases of 
MBC were obtained from the SEER database in their study. Results indicated that 87.4% 
used mastectomy and 12.6% used breast-conserving surgery (Fields et al., 2013). Fields 
et al. concluded that the outcomes for MBC improve with therapy use in unscreened 
populations. 
Jablon (2014) conducted a study with a sample of 1,951 men who had localized 
breast cancer and found that 70% of the participants had had a lumpectomy with 
radiation. Results highlighted the need for men to be offered mastectomy instead of 
lumpectomy. The justification for this procedure is that men often have central tumors 
around the nipple area, meaning that surgery can be performed without sacrificing the 
nipple. Nipple reconstruction also might be done surgically, and some patients would 
rather tattoo in order to restore body image (Fentiman et al., 2006). 
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Deciding on the treatment to follow is customized to the stage at presentation. A 
sentinel lymph node biopsy is an option for patients with MBC, but limited data have 
been available to prove the effectiveness of this option (Fentiman et al., 2006; Giordano, 
2005; Gómez-Raposo et al., 2010). Most research has found support for adjuvant 
hormonal therapy, radiotherapy, and chemotherapy for MBC, as is the case for women 
with breast cancer (Fentiman et al., 2006; Giordano, 2005; Gómez-Raposo et al., 2010). 
Tamoxifen is one of the most recommended adjuvant hormonal therapies, even though 
data relevant to MBC patients have been scant (Fentiman et al., 2006; Giordano, 2005; 
Gómez-Raposo et al., 2010). More research is needed to better understand MBC and 
improve its management and prognosis (Constantinou & Fentiman, 2012; Gómez-Raposo 
et al., 2010).  
Literature Review Related to Key Variables and/or Concepts 
Social networking is a strong medium of communication that reaches 
communities, provides social and family support, and is linked to the framework of the 
research. The constructs of the social determinants of health framework include 
psychosocial predictor variables such as anxiety, depressive symptoms, distress, body 
image, coping mechanism, and emotional support. These predictors can encourage 
healthy choices and lifestyles, both of which have a strong influence on health and the 
ways in which people cope with demanding life issues and circumstances. Social support 
includes practical assistance; financial help; and the availability of information, advice, 
and psychological support.  
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Anxiety, a construct in the social determinants of health framework. is tied to the 
emotional support available to MBC patients. Lack of economic resources, such as loss 
of work as the disease progresses, will mean a reduction in income. This is a significant 
time when MBC patients need social and family support. Anxiety can lead to a potential 
increase in depressive symptoms, the second construct in the framework. MBC patients 
need additional emotional support during this phase of the disease to reduce distress, the 
third construct. Isolation; lack of social support; low self-esteem, which is part of body 
image; self-blame; and hopelessness can affect their ability to cope with a diagnosis of 
MBC.  
The effects of practical and emotional support have been studied. According to 
Lyyra and Heikkinen (2006), MBC patients lacking emotional support were 2.5 times 
higher than those who had emotional support in terms of the decision to have a 
mastectomy. Ostberg and Lennartson (2007) reported that individuals with diverse 
sources of support have better health outcomes. 
In conclusion, the social determinants of health framework was a sound 
foundation for this study. The framework supported and reinforced the basic constructs of 
this study, which was centered on the social support construct of the framework. The 
purpose of this study was to understand the influence of the predictors of age; race; and 
grade of cancer (I, II, or III) on the outcome of mastectomy in MBC. 
Summary and Conclusions 
Chapter 2 summarized the major literature related to the predictors of mastectomy 
in Grade II or Grade III of MBC; diagnosis; staging; and treatment options. I reviewed 
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the variables and discussed the social determinants of health framework as it was used in 
the current study. This research will fill gaps in the literature relevant to the topic of 
MBC. In Chapter 3, I describe the methodology, my role as the researcher, instrument 
used, informed consents, sample and target population, and the recruitment and approval 
processes necessary to conduct the research.  
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Chapter 3: Research Method 
Introduction 
  The purpose of this study was to understand the influence of the predictors of age; 
race; and grade of cancer (I, II, or III) on the outcome of mastectomy in MBC. This 
chapter explains the study design, sample, and procedures. Although the analysis of 
secondary analysis data is flexible and can be used in several ways, it also is an empirical 
exercise and an efficient method with procedural and evaluative stages, just as in 
collecting and evaluating primary data (Katsirikou, 2013). This study confirmed that 
secondary data analysis is a viable process of inquiry when a systematic procedure is 
followed and presents an illustrative research application using a quantitative analysis 
(Katsirikou, 2013). I used this medium to test the RQs and provide an explanation of the 
answers to the RQs using what Creswell (2009) described as a quantitative research 
design. “Quantitative analysis should contain the quantifiable variable by observation 
performed retrospectively, which varies on institution or organization” (Creswell, 2009, 
p. 50). I followed a quantitative research design to compute the contributory relationship 
obtained during the MBC survey with the numeric data through a secondary data 
approach (Creswell, 2009).  
Study Design and Rationale 
The purpose of this cross-sectional survey was to generalize the results from the 
target population of MBC patients so that inferences can be made about the influence of 
age; race; and grade of cancer (I, II, or III) on the outcome of mastectomy in MBC.  
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Research Design and Approach  
This quantitative study followed a retrospective design. Secondary data collected 
between 2011 and 2013 were retrieved from the SEER database of the NCI. Secondary 
data were suitable for use in this study based on the limited data available across the 
United States and Europe on BRFSS and quality of life on survivorship data. I conducted 
this retrospective study to review the differences in MBC stage at diagnosis, demographic 
data, tumor size, and sociological variables from 2011 to 2013 previously surveyed in 
order to address the RQs. The purpose of this study was to understand the influence of 
the predictors of age; race; and grade of cancer (I, II, or III) on the outcome of 
mastectomy in MBC. The results highlighted the issue of health care availability, health 
care practices, and the need for education and information about MBC.  
Research Questions and Hypotheses 
RQ1: How will age impact knowledge related to mastectomy in MBC? 
H01: Age will not relate to mastectomy in MBC. 
Ha1: Age will relate to mastectomy in MBC. 
RQ2: How will race account for MBC in relation to mastectomy? 
H02: Race does not account for MBC in relation to mastectomy. 
Ha2: Race does account for MBC in relation to mastectomy.  
RQ3: Is there a predictive relationship between mastectomy and Grade I, II, or III 
cancer in MBC? 
H03: There is no predictive relationship between mastectomy and Grade I, II, or 
III cancer in MBC. 
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Ha3: There is predictive relationship with mastectomy and Grade I, II, or III 
cancer in MBC. 
All RQs were analyzed using logistic regression. Modeling included all risk 
factors mentioned earlier, in addition to all demographic variables. I also included data 
from more than 427 patients after inclusion of my variables; data from the SEER 
database on other cancer stages were excluded.  
The sample size calculation formula was as follows: 
 
ss = 





Z = Z value (e.g. 1.96 to 95% confidence level)  
p = percentage picking a choice, expressed as decimal  
(.5 used for sample size needed) due to the number of mastectomies was hoped to be at 
50% of MBC 
c = confidence interval (CI), expressed as decimal (e.g., .04 = ±4) 
Sample size 427; 95% confidence using a U.S. standard population of 100,000, at a 50% 
MBC the CI (4.73), at 99% sample size 427 confidence using the same 100,000 pop at 






persons with a given health indicator during a specified time period 




 100,000 X 100 = 0.12% 
 Per 100,000 standard population 
 
Methodology 
Knowing that there were inadequate resources regarding time, money, and the 
number of MBC cases available prompted the use of a retrospective cohort study as a 
suitable design. The IVs in this study were age; race; and grade (I, II, or III) of cancer; 
the DV was outcome of mastectomy. The purpose of this study was to understand the 
influence of the IVs on the DV. 
Setting and Sample  
Data on male patients of all racial and ethnic groups reported from the 17 
registries that provide information to the SEER database who had been diagnosed with 
breast cancer between 2011 and 2013 served as the target population. The sample 
comprised data on men diagnosed with breast cancer based on the following criteria:  
(a) 18 years of age and older, (b) residing in the United States, (c) year of diagnosis: 2011 
to 2013 inclusive; (d) tumor size, (e) race/ethnicity: all races/ethnicities reported;  
(f) grade of cancer at diagnosis; and (g) mastectomy. Stratification of Grades II and III 
from the secondary data commenced once approval was received and the confidentiality 
agreement was signed.  
Informed Consent 
I assumed that informed consent had been given by the men whose data were 
reported to the SEER database to the original investigators. Using archival data meant 
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that I did not have to obtain any further consent from any of the original participants and 
that I could conduct a secondary analysis freely (Grinyer, 2009).  
The 17 registries obtained information about the participants’ ages; race; and 
grade of cancer (I, II, or II), along with mastectomy status, by using an interview 
protocol. I assumed that they had conducted these interviews following confidentiality 
and HIPPA compliance protocols. All documents related to the study are stored in a 
secured and fireproof cabinet under key and lock. They will remain there for 5 years after 
publication of the data, after which time all data will be shredded or electronically 
destroyed. 
Instrumentation and Materials 
I obtained archival data from the NCI’s SEER database. SEER, since its inception 
in 1973, has collected information on cancer incidence and survival rates from 17 
population-based registries in geographic areas that make up 26% of the U.S. population 
(Klein et al., 2011; SEER, n.d.a). The SEER registry database is a wide-ranging source of 
U.S. population-based information and includes data on stage of cancer at diagnosis and 
patient survival rates. SEER collects and stores demographic data on patients, primary 
tumor site, morphology, and stage at diagnosis (Klein et al., 2011). Participating 
registries are required to provide data collected on primary tumor site, tumor 
morphology, type of treatment, and follow-up for survival status (Klein et al., 2011).  
  NCI staff work directly with registries that are part of the North American 
Association of Central Cancer Registries (NAACCR) to support them in confirming that 
the data are of high quality and the data can be pooled to obtain national estimates (Klein 
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et al., 2011). The NCI personnel accountable for supervising the SEER database also act 
as liaisons with registries and other organizations involved with cancer surveillance 
(Klein et al., 2011).  
In the early part of 1973, the SEER database began collecting statistics on cancer 
cases in Connecticut, Hawaii, Iowa, New Mexico, and Utah, along with the metropolitan 
areas of Detroit and San Francisco-Oakland (Klein et al., 2011). The metropolitan area of 
Atlanta and the 13 counties in the Seattle-Puget Sound areas were added to the database 
from 1974 to 1975 (Klein et al., 2011). In 1978, 10 predominantly African American 
counties in Georgia were added, and American Indians residing in Arizona were added in 
1980. According to SEER, the following three geographical areas participated in the 
SEER program prior to 1990: New Orleans, Louisiana (1974-1977, rejoined 2001); New 
Jersey (1979-1989, rejoined 2001); and Puerto Rico (1973-1989).  
  The NCI receives financial support from the government, allowing it to collect 
information on cancer cases, including Alaska Native populations (Klein et al., 2011). In 
1992, expansion of the SEER database saw the inclusion of minority populations, 
particularly Hispanic Americans, through the addition of Los Angeles County and four 
counties in the San Jose-Monterey area south of San Francisco (Klein et al., 2011). In 
2001, thanks to the availability of funding, SEER database coverage was expanded to 
Kentucky, the remaining counties in California (Greater California), New Jersey, and 
Louisiana (Klein et al., 2011). The SEER database identifies the 17 national registries 
that their case data originate.  
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Cancer data at the state level are confidential and protected by legislative efforts 
(Klein et al., 2011). These efforts are very specific as to whom cancer information is 
reported to, how it is reported, and the procedure for accessing it (Klein et al., 2011; 
SEER, n.d.b). There is no identifying information on any SEER data, and permission is 
required before access to the data can be obtained.  
Data Collection and Analysis  
I used archival data from 2011 to 2013 obtained from the SEER database. The 
data were extracted manually with the help of SEER professionals and analyzed using 
SPSS v.23. The benefit of using the SEER data set is that it is a comparatively 
inexpensive way to obtain national data specifically on cancer. One benefit of using SPSS 
v.23 is its huge data set capacity and capability to analyze the data statistically. MBC 
cases were dichotomized to the United States based on place of residence identified at 
time of diagnosis. The study focused on three components (i.e., grade of cancer at 
diagnosis, age, and mastectomy) to better define regional differences. 
Inclusion criteria were all MBC cases and all ages reported to the SEER database 
between 2011 and 2013. The stage at diagnosis has been provided to or recorded by 
SEER since 1975. Information about tumor size has been available only since 1988. 
Hence, the SEER database was examined for all MC cases diagnosed from 2011 to 2013 
so that data on stage and tumor size could be captured for all cases. Lymph node 
involvement was not included as a variable in the stage of disease definition because it 
could have complicated the statistical analysis (Rosenbaum et al., 2004).  
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Quality Control and Quality Assurance  
  The SEER database is recognized as the gold standard for data quality worldwide 
(Klein et al., 2011). To ensure the safety and confidentiality of the retrieved data, all 
digital information was stored on a home office computer, and Internet access was 
protected by a firewall built into the DSL modem and one built into the Windows XP® 
operating system. Data and files were backed up daily, and backups were maintained on a 
network drive on a server encrypted or protected by the two firewalls. My personal 
computer is password secured, and only I have access to the records (Klein et al., 2011). 
Threats to Validity 
 The most recognized limitation regarding the use of secondary data for analysis 
is that the data sometimes are collected for purposes that might not align with other 
researchers’ investigations (Boslaugh, 2007). Another major disadvantage of using 
secondary data is that secondary researchers do not participate in the data collection 
process or know how it was conducted, nor do they know of any issues that might have 
arisen, such as low response rates or participants lacking an understanding of survey 
questions. Secondary researchers might have to find this information through other 
sources, such as documentation of the data collection procedures, technical reports, and 
publications (Boslaugh, 2007). It is difficult to calculate the approximate number of the 




I received approval from Walden University’s Institutional Review Board (IRB 
approval #09-15-15-0185323) to conduct this study. A letter of approval from the 
investigators to use their article for research is in the Appendix.  
Possible Types and Sources of Information or Data 
All RQs and hypotheses were analyzed using logistic regression. Modeling 
included all risk factors listed in Chapter 1 and 2, in addition to all demographic 
variables.  
Protection of Human Subjects 
Cancer registry professionals are obligated to protect the confidentiality of cancer 
patient information (Klein et al., 2011). Each cancer registry can impose additional 
policies regarding how files and documents are handled (Klein et al., 2011; SEER, n.d.d). 
Data retrieved from the SEER program are anonymous, so there is no way to extract 
additional personal demographic information about any participants, aside from broad 
information (such as sex and race) available on the database that can be used for research 
purposes (Klein et al., 2011). The data became available to me once I signed the SEER 
data use agreement (SEER, n.d.a).  
Summary 
Chapter 3 explained the methodology used in this quantitative study of 
 secondary data. Included was information about the rationale for the research design and 
approach, the data source and sample, instrumentation, data collection and analysis, IV, 
DVs, and RQs. I also discussed quality assurance and the protection of human subjects.  
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Chapter 4: Results 
Introduction 
Chapter 4 briefly reviews the purpose of the study and presents the results of the 
analysis of the archival data obtained from the SEER database. The purpose of this study 
was to understand the influence of the predictors of age; race; and grade of cancer (I, II, 
or III) on the outcome of mastectomy in MBC. The management of MBC has been 
generalized more on disease epidemiology, genetics, and survivorship only; thus, there 
were insufficient data to support an investigation into psychosocial well-being.  
Data Collection 
Inadequate resources relevant to time, money, and the number of MBC cases 
available prompted the use of archival data from the SEER database to complete the 
study. The data were extracted and analyzed using SPSS v.23. To complicate the process, 
I could not compare data from 2010 and earlier to data from 2011 onward because of a 
change in the methodology of the BRFSS. Prior to 2011, cell phone data were not 
included in the BRFSS, making 2013 only the third year that cell phone data were 
included in the files. The official Center for Medicare and Medicaid Services (2012) 
weighting schematic was different prior to 2011, so I did not combine data from 2011 
forward with data from 2010 and earlier. The estimates obtained from using the weights 
for landline and cellphone interviews were not comparable to 2010 and earlier and were 
not compared or added to current trend graphs.  
I used the SEER database to obtain data from 2011 to 2013 about men diagnosed 
with breast cancer. SEER collects SES data such as education or family income on a 
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national level, but not on an individual level (SEER, 2016). The average reported age of 
MBC cases was 69 years of age. The IVs of this study were age; race; and grade of cancer 
(I, II, or III). The DV was mastectomy. 
Setting and Sample 
I analyzed SEER data from 2011 to 2013 on male patients diagnosed with breast 
cancer. These data comprised the sample. To be eligible to be in the study, the SEER data 
had to reflect the following criteria: (a) males 18 years of age and older with breast 
cancer, (b) United States as the country of residence, (c) age at diagnosis, (d) year of 
diagnosis: 2011-2013 inclusive, (e) tumor size, (f) all races/ethnicities reported in the 
SEER database, (g) stage of cancer at diagnosis, and (h) mastectomy. 
Sample Characteristics 
I obtained 2011-2013 SEER data from 427 MBC patients. The number of cases in 
parentheses was extracted from the database based on age group: 35-39 (n = 6), 40-49  
(n = 18), 45-49 (n = 29), 50-54 (n = 26), 55-59 (n = 46), 60-64 (n = 62), 65-69 (n = 84), 
70-74 (n = 59), 75-79 (n = 29), 80-84 (n = 33) and 85 and older (n = 35). The average 
reported age of the participant was 65 to 69 years. As seen in Table 3, data were retrieved 
for 73 Black men (17%), 335 White men (78%), and 16 Other (4%). I completed the 
analysis based on MBC patients, with the greatest reported number in terms of age was 
84 men between 65 years and 69 years (19.6%). Table 4 further reports mastectomy by 
race, so the total number of Black mastectomy cases was 20 (17%), White was 89 (77%), 




Table 3  
Sample Characteristics for Age and Race MBC SEER Data 2011-2013  
 
Table 4  
MBC Mastectomy Cases by Race 2011-2013 
   Mastectomy   
Age MBC Mastectomy total Black White Other Unknown 
35-39 6   2   
40-44 18  2 4   
45-49 29  2 5 1  
50-54 26  1 5 2  
55-59 46  2 11 1  
60-64 62  4 14   
65-69 84  5 17 1  
70-74 59  1 12   
75-79 29   4   
80-84 33  3 10 1 1 
85+ 35   5   
Total 427 116 20 89 6 1 
 
Table 5 shows the increase in the number of MBC cases by year reported by the 
17 cancer registries across all U.S. states except Texas. The number was 130 in 2011, 137 
in 2012, and 159 in 2013. Of these 427 cases, 55 had a diagnosis of Grade I cancer, 190 
had a diagnosis of Grade II cancer, and 182 had a diagnosis of Grade III cancer. Of the 
total for all 3 years, 116 men had undergone mastectomy.  
  
Age  No. of cases extracted from data Black White Other 
35-39 6 1 5 0 
40-44 18 3 14 1 
45-49 29 6 21 2 
50-54 26 5 20 1 
55-59 46 8 36 2 
60-64 62 14 47 1 
65-69 84 17 65 2 
70-74 59 7 49 3 
75-79 29 4 24 1 
80-84 33 4 28 3 
85+ 35 2 33 0 
Total 427 73 335 16 
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Table 5  
MBC Cases by Year: 2011-2013 SEER Data 
2011 2012 2013  Grade I Grade II Grade III Mastectomy 
130 137 160 55 190 182 116 
Note. One case had Grade IV cancer 
 
The IVs of this study were age; race (Black, White, and Other); and grade of 
cancer (I, II, or III) in the United States. The DV was mastectomy. Logistic regression 
analyses were based on chi-square analyses conducted to test significance for all 
hypotheses; correlations to rule out multicollinearity were run among all IVs having a 
Pearson’s r ≤ .000. Most relationships were statistically insignificant because alpha was  
≥ .05). 
  Regression analysis was conducted on White MBC patients according to age 
group; the mean age was 65 years. Mastectomy information on White MBC patients is 
displayed in Table 6 by categorical group 35 to 85 years: 35 to 39 years (n = 2, 0.5%); 40 
to 44 years (n = 6, 1.4%); 45 to 49 years (n = 8, 1.9%); 50 to 54 years (n = 8, 1.9%); 55 to 
59 years (n = 14, 3.3%); 60 to 64 years (n = 19, 4.4%); 65 to 69 years (n = 23, 5.5%); 70 
to 74 years ( n = 13, 3.0%); 75 to 79 years (n = 4, 0.9%); 80 to 84 years (n = 14, 3.3%); 
and 85 and older (n = 6, 1.4%). For the current study, results showed that the prevalence 
of mastectomy among men with MBC increased significantly among White patients, less 




Table 6   
 
White MBC Patients by Age Group 
 
Valid N Missing % n % N % 
AGE * 35-39 2 0.5% 425 99.5% 427 100.0% 
AGE * 40-44 6 1.4% 421 98.6% 427 100.0% 
AGE * 45-49 8 1.9% 419 98.1% 427 100.0% 
AGE * 50-54 8 1.9% 419 98.1% 427 100.0% 
AGE * 55-59 14 3.3% 413 96.7% 427 100.0% 
AGE * 60-64 19 4.4% 408 95.6% 427 100.0% 
AGE * 65-69 23 5.4% 404 94.6% 427 100.0% 
AGE * 70-74 13 3.0% 414 97.0% 427 100.0% 
AGE * 75-79 4 0.9% 423 99.1% 427 100.0% 
AGE * 80-84 14 3.3% 413 96.7% 427 100.0% 
AGE * 85+ 6 1.4% 421 98.6% 427 100.0% 
N = 427 
 
Initially, I planned to conduct hierarchical multiple linear regression analyses only 
(see Tables 7, 8, 9, 10, 11, & 12). For multiple linear regression, R, or the coefficient of 
determination, is used as a measure of effect size, namely, the adjusted R2. Although 
results for the multiple linear regression showed that the IVs of Age and White race were 
significant, the effect sizes (adj. R2) for all models were undetectable, indicating no 
meaningful or practical significance. The data were then analyzed using hierarchical 
logistic regression, with the DVs being treated as dichotomous. I reported only logistic 
regression analysis results. Logistic regression, particularly binary logistic regression, is 










t Sig 95% CI for B 
 B SE Beta   Lower bound Upper bound 
Age 0.873 0.076 0.780 11.438 0.000 0.723 1.022 
Grade I -7.47E-15 0.130 0.000 0.000 1.000 -.256 0.256 
Grade II 4.79E-14 0.090 0.000 0.000 1.000 -.176 0.176 
Grade III -6.54E-14 0.097 0.000 0.000 1.000 -.191 0.191 
Black -4.04E-14 0.097 0.000 0.000 1.000 -.191 0.191 
White 1.27E-01 0.031 0.118 4.052 0.000 -.066 0.189 
Other 3.04E-15 0.109 0.000 0.000 1.000 -0.215 0.215 
Note. DV was mastectomy 
 
 Table 8  
Chi-Square Tests for Age  
 Value df 
Asymptotic Sig. 
(2-sided) 
Exact Sig.  
(2-sided) 
Exact Sig.  
(1-sided) 
Pearson chi-square 28.718a 1 .000   
Continuity correctionb 27.153 1 .000   
Likelihood ratio 46.120 1 .000   
Fisher’s exact test    .000 .000 





Age and Mastectomy 
 B SE Wald df Sig. Exp(B) 
Step 0 Constant .986 .109 82.172 1 .000 2.681 
Note. Variable in equation is age. 
 
Table 10 
Omnibus Tests of Model Coefficients Age 
 Chi-square df Sig. 
Step 1 Step 286.785 1 .000 
Block 286.785 1 .000 




Table 11  
Logistic Regression: IV of Mastectomy and IV of White Race 







-20.567 4190.415 .000 1 .996 .000 .000  
Constant 21.203 4190.415 .000 1 .996 1615476258.503   




White Chi-square df Sig. 
Step 1 Step 67.288 1 .000 
Block 67.288 1 .000 
Model 67.288 1 .000 
 
 
Independent Variables  
Age. RQ1: How will age impact knowledge related to mastectomy in MBC? Null 
Hypothesis 1 is rejected because p ≤ .05, meaning that it was statistically significant  
(β =.780, t = 11.438 [see Table 7]; (p < .05); chi-square test p = .000 [see Table 8 and 
Table 10])). Therefore, Alternative Hypothesis 1 is accepted.  
Race. RQ2: How will race account for MBC in relation with mastectomy? 
Analysis was as follows: Black (β = 0.000, t = .000 [see Table 7]; p = 1.000 (p > .05); 
chi-square test [see Table 8]); White (β = 0.118, t = 4.052 [see Table 7; (p = .000) and (p 
≤ .05) therefore statistically significant; chi-square test [see Table 12]); and for Other race  
(β = 0.00; t = .000 [see Table 7]; (p >.05), Other race is statistically insignificant (p = 
1.000; p > .05). Data for White were statistically significant (p < .05), so Null Hypothesis 
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2 is rejected, and Alternative Hypothesis 2 is accepted. The data for Black and Other 
cases were insignificant (p =1.000; p > .05), which was greater than  
(p > .05). Therefore, the null hypothesis is accepted, and the alternative hypothesis 
rejected for Black and Other race categories; the null hypothesis is rejected for White 
race only.  
Grade. RQ3: Is there a predictive relationship between mastectomy and Grade I, 
II, or III cancer in MBC? Results shown on Table 7 were as follows: Grade I  
(β = 0.000, t = .000, p = 1.000); Grade II (β = 0.000, t = .000, p > 1.000); and Grade III (β 
= 0.000, t = .000, p > 1.000). All three grades were statistically insignificant (p < .05). 
Therefore, Null Hypothesis 3 is accepted, and Alternative Hypothesis 3 is rejected. Data 
from 116 of the 427 MBC patients (27.1%) reported having been treated with 
mastectomy at a later grade (II or III) of cancer; 311 (72.8%) reported receiving hormone 
therapy, but no surgery (see Table 7). 
Dependent Variable of Mastectomy 
   As already mentioned, 116 (27.1%) of the 427 MBC cases reported having 
mastectomy at a later stage of cancer, whereas 311 (72.8%) reported receiving hormone 
therapy (see Table 13). In Table 9, mastectomy correlated at a significant level (p ≤ .000) 
on age, and significant (p < .05; p = .000); chi-square test [see Table 12]) on race, thus 





Table 13  
Mastectomy as the DV 
Classification table 
 Observed Predicted 
 Mastectomy % correct 
 Yes No 
Step 0 Mastectomy Yes 0 116 .0 
No 0 311 100.0 
Overall percentage   72.8 
a. Constant was included in the model. 
b. Cut value was .500 
 
Logistic Regression Analysis 
Table 7 showed the logistic regression analysis that was conducted; the p-value of 
< .05 was considered statistically significant. Table 7 showed the logistic regression of IV 
and DV. Age β = .780, standard error of 0.076 with a t value of 11.438 and age statistical 
significance (p < .05; chi-square test p = .000), the 95% interval for B lower bound was 
0.723 and upper bound was 1.022. For race, Black (β = 0.000, t = .000, statistical 
insignificance (p > .05; p = 1.000 chi-square test) t = .000, 95% lower -.191 and upper 
.191. White (β = 0.118 and t = 4.052, (p < .05; p = .000 chi-square) 95% interval lower -
0.066 and upper 0.189. Grade I t = 0.000 sig 1.000, which was statistically insignificant p 
≥ .05; 95% interval lower -0.256 and upper 0.256. Grade II, t = 0.000 (p = 1.000 p > .05) 
statistically insignificant, 95% interval lower -.176 and upper .176. Grade III, t = 0.000, 
(p = 1.000 p > .05); 95% interval lower -.191 and upper .191. 
Statistical Analysis 
  SPSS v.23 was used to compute the results. The first stage of the analysis 
involved descriptive statistics of the preliminary associations among age; race; and grade 
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of cancer (I, II, or III). However, the DV of mastectomy outcome was tested against the 
three IVs using independent t tests for the dichotomous variables and Pearson’s product-
moment correlations for the continuous variables. For independent t tests, all were 
significant (p = .000; p < .05). Levine’s test for equality of variances was studied to 
account for the possibility of an unequal variance of samples. For example, Table 14 
shows F = 121.271 and that the values were statistically significant (p = .000; p < .05). 
Separate variance estimates also were reported. Table 14 is a model summary of logistic 
regression, where R is .818a, F = 121.271, df = 7, and sig F change p = .000. 
Table 14 
Model Summary IV 
Model summary 
Model 
R R2  Adj. R2 SE of the 
estimate 
Change statistics 
R2 change F 
change 
df1 df2 Sig. F 
change 
1 .818a .670 .664 .258 .670 121.271 7 419 .000 
a. Predictors: (Constant), OTHER, WHITE, AGE, GRADE I, GRADE II, GRADE III, BLACK 
 
In conclusion, drawn from the MBC study, p > .05 because the output read  
p 1.00 statistically, insignificant predictors for Grade I, Grade II, Grade III used to test 
against mastectomy. However, measures of age and race were statistically significant in 
the White population of MBC, where β = .118, t = 4.052; (p = .000; p < .05) and age  
β =. 780 t = 11.438 and (p = .000, showing is p < .05).  
Summary 
  Chapter 4 presented the results of the analysis of archival data from 2011 to 2013 
obtained from the SEER database to examine the prevalence of MBC in terms of age, 
race, and grade of cancer as the IVs and mastectomy outcome as the DV. A total of 427 
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cases from SEER archival data were examined. Results of the study will add to 
knowledge of MBC in United States. Chapter 5 summarizes and interprets the findings 




Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of this study was to understand the influence of the predictors of age; 
race; and grade of cancer (I, II, or III) on the outcome of mastectomy in MBC.  
Logistic regression analyses were based on chi-square analyses conducted to test 
significance for all hypotheses, all IVs significantly predicted, and added to the predictive 
variables and were all related to mastectomy. Prior to logistic regression analyses, 
correlations to rule out multicollinearity were run among all IVs in the analysis, which 
successfully produced a Pearson’s r < .000.  
Interpretation of the Findings 
I extracted archival data dating from 2011 to 2013 from the SEER database to 
study the relationship between the IVs of age, race, and grade of cancer, and the DV of 
mastectomy among men diagnosed with MBC. Breast cancer has a range of specific 
stressors that can threaten men’s emotional well-being after mastectomy. Examples of 
these postsurgery stressors are concerns about masculinity and the sense of isolation 
associated with a lack of support and not knowing where to seek for information (Brain et 
al., 2006). A general lack of awareness and information can inhibit the support needed to 
deal with MBC. Sociopsychological factors affecting well-being that were not included in 
this study but might be considered in future studies are the use of avoidance coping 
strategies, fear and uncertainty about the future, altered body image, and unmet 
information needs in relation to breast cancer and mastectomy. A larger study might help 
to identify the impact of these variables on the psychosocial well-being of men 
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experiencing various grades of MBC as well as stages of MBC that have yet to be 
studied.  
There have been many studies of age, race, grades of cancer, and coping in regard 
to women who have been diagnosed with breast cancer, but few studies have focused on 
male cancer patients. Although past results have confirmed that age and race can predict 
poor adjustment to breast cancer (Brain et al., 2006), further research is needed to explore 
the relationship of the IVs of age, race, and grade of cancer to the DV of mastectomy 
experienced over the course of breast cancer.  
Limitations of the Study 
 Because I analyzed secondary data and had no involvement in the initial 
collection of primary data, I was unable to follow up with or reach out to the participants 
directly, making the generalizability of the findings unclear. Another disadvantage of 
using archival data was that I did not participate in the data collection process, making it 
difficult to calculate the approximate number of the men who were initially enrolled 
rather than the number who were reported in the SEER database. The archival data were 
limited because the questions were not evenly asked during the 2011-2013 period in most 
states. 
Source of Bias 
 Sources of bias were very limited, but the initial questions did not indicate 
whether the MBC archived data were obtained only from men because there was no 
indication of transgender issues reported for MBC by the SEER submitters. Questions 
were not evenly asked in all states during the 2011-2013 data collection period. In 
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addition, the psychosocial unavailability in the database created a setback during the 
analysis, leading to challenges while extracting the data for this study.  
Reliability and Validity 
 Responses to the questionnaire submitted by the original investigators to the 
SEER database through the BRFSS were checked for reliability and validity by double-
checking the data source for accuracy and source confirmation. Internal validity also 
presented additional limitations because these were secondary data. Extraction was 
meticulously double-checked from the original data for errors, so the external validity 
was not a challenge because of the large sample size of the study from the SEER 
database. 
Recommendations for Future Research 
Future researchers should focus on assessing the specific educational and social 
needs of men with breast cancer, along with their experiences as patients in the medical 
community and as members of society. Cooperative groups could be formed throughout 
the United States and other countries to provide information about the impact of cultural 
diversity on the experience of MBC. This information could give counselors the 
opportunity to better tailor counseling sessions to meet the unique needs of men with 
breast cancer. It is important to recognize the individuality of each MBC patient, 
regardless of age and race, and the shared experiences that men with breast cancer 
experience. The challenge is to incorporate knowledge of these shared experiences with 
each man’s unique personality and life experience to devise health care plans that will 
70 
 
enable these men to make the best decision not only for their families but also for 
themselves.  
Implications for Positive Social Change 
This study emphasized the need for increased awareness and information about 
MBC. Having a disease that affects predominantly women can threaten a man’s sense of 
masculinity and engender feelings of isolation. Men might benefit from receiving 
information early in the referral process about: treatment options, side effects, symptoms, 
survival rates, cancer reoccurrence, and the potential impact on quality of life and body 
image after undergoing mastectomy.  
Health care professionals play an important role in providing information and 
support to men with breast cancer about the availability of formal support networks. 
Practical suggestions for improving information and awareness include disseminating 
leaflets with information on MBC and a photograph of a critical male mastectomy, 
supporting local matching schemes and telephone help-lines, and raising public awareness 
through the media. Insurance companies should provide men and women with annual 
mammograms. This preemptive measure could lead to more acceptance of men having 
mammograms and much earlier detection of MBC. 
Men might be less likely than women to disclose distress and seek help, so it is 
possible that health care providers might be underestimating the psychosocial impact of 
breast cancer on men. Screening distress is essential so that men who might benefit from 
additional emotional support can be identified early in the referral process. General 
screening tools such as the Hospital Anxiety and Depression Scale, which asks about 
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anxiety and depression, might underestimate the prevalence of distress in men with breast 
cancer, so disease-specific measures such as the Impact of Event Scale, another 
questionnaire that asks distress questions, should be used in combination with the 
Hospital Anxiety and Depression Scale to give future researchers easy access to the data.  
Conclusion 
The present study adds knowledge to the literature by using archival data from the 
SEER database to understand the influence of the predictors of age; race; and grade of 
cancer (I, II, or III) on the outcome of mastectomy in MBC. However, future research is 
needed to expand the present findings. The lack of dedicated resources and research 
focusing on MBC patients in the United States highlights the need for psychosocial 
support such as counseling services for men who have breast cancer. The most critical 
social change is to ensure the timely dissemination of MBC to reach men, regardless of 
age or location.  
Discussion 
Much of the research on MBC has been extrapolated from research on the 
incidence of female breast cancer, likely because of the infrequent incidence of MBC. 
The purpose of this study was to understand the influence of the predictors of age; race; 
and grade of cancer (I, II, or III) on the outcome of mastectomy in MBC. Based on the 
theory of projection, a concern would be that these feelings could exacerbate the shame 
and confusion that men with MBC experience, particularly because breast cancer is 
considered a cancer specific to women. Men with MBC feel there has been a lack of 
educational aids dedicated to the needs of men. Typically, men present in the denial 
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stage, questioning their sexual orientation, masculinity, and belief in God regarding their 
diagnosis of breast cancer. 
 A mastectomy is considered as making significant alterations to the male self-
image and having the potential to impact male sexuality. Mastectomy scars are 
concerning to men in that they feel that society will consider them as feminine. This 
study examined how age; race; and grade of cancer (I, II and III) influenced mastectomy 
following a diagnosis of MBC.  
Age was a psychosociological predicator variable. As a construct in the social 
determinants of health framework, age was statistically significant in the White 
population of men diagnosed with MBC. Age also determined how well the MBC 
patients handled anxiety in terms of worry and fear whenever the symptoms became 
more severe or when undergoing testing to determine whether the cancer had progressed. 
The younger MBC patients were the most concerned about body image. 
Some of the most common fears for all ages of MBC patients studied were the 
painful procedures associated with the disease and such side effects as hair loss, nausea, 
fatigue, and pain. Younger MBC patients worried about disruptions to their daily lives 
that led to fear and anxiety because of their inability to work. Older MBC patients who 
had already reached retirement worried less. 
Race is another construct in the social determinants of health framework. Racial 
disparities existed in the management of MBC in terms early diagnosis and access to 
health care. Race also was statistically significant in the White population of MBC. Most 
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White patients were insured, but Black patients were underinsured because of the lack of 
social support, poor employment prospects, and lack of resources.  
Adding to the social determinants of health framework, grade of cancer refers to 
the aggressiveness of its management. Grade I cancer is a low grade; in Grade II cancer, 
cells become differentiated and require treatment; and in Grade III cancer, the cells grow 
and spread rapidly. MBC patients in this study who were at this latter stage reported 
frustration, emotional distress, and the inability to cope. Grade I denial in breast cancer 
can lead to deregulation of the immune system and results in long-term physical and 
emotional problems that cause distress. Many patients with Grade 1 cancer who are 
waiting for MBC test results experience tremendous distress. 
Grade II is another construct of the social determinants of health framework. 
MBC patients generally seek a mastectomy during Grade II, and depending on the 
relationships that they have with partners or caregivers, they report body image issues in 
an effort to seek emotional help to deal with the disease. Caregivers or partners might 
offer advice about treatment options such as breast-conserving surgery or reconstructive 
surgery, to enhance body image caused by mastectomy (Rab, 2012). 
Grade III is another construct in the social determinants of health framework. 
MBC patients with this grade of cancer need help coping with the effects of 
chemotherapy on MBC. Most patients with Grade III MBC also seek mastectomy.  The 
MBC patients in my study reported very poor physical and emotional QOL when coping 
with the treatment regimen. The side effects of antiestrogen during treatment can include 
weight gain, fatigue, and depression; mastectomy can lead to worry about body image 
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(Rudy & Winer, 2013). Because of the side effects of treatment, regardless of the grade 
of cancer, men with MBC need emotional support (Brain et al., 2006). 
Psychosocial comorbidities also had a negative effect on the emotions of the 
patients with MBC in my study. Feelings of uncertainty gave rise to feelings of 
hopelessness, and the absence of social networks was noted as leading to decreased 
survival rates and a rapid increase in the course of the disease. The prediction of 
psychosocial variables needs to be tested in future research so that practitioners can help 
MBC patients to manage the disease. Researchers also might want to consider 
investigating the understudied general cancer-related distress, anxiety, and depressive 
symptoms and depression experienced by patients with MBC during chemotherapy. 
MBC patients who have Grade I, Grade II, or Grade III MBC who have undergone 
mastectomy also have body image issues. Unfortunately, none of this information was 
reported in the SEER database.  
In addition, future researchers should encourage MBC patients to discuss the 
cancer experience with others in order to facilitate the cognitive processing required for 
positive reframing, a finding with important implications for psychosocial interventions. 
Finding literature related to MBC that focused on age; race; and grade of cancer (I, II, 
and III) was challenging. Men who are struggling with MBC are withdrawn and reluctant 
to participate in research. Therefore, I recommend that financial incentives be provided to 




Finally, the interpretation of the findings requires caution because the study was 
conducted with archival data. Measurement issues pertaining to the validity and 
reliability of the instruments used were clarified by SEER personnel, who stated that the 
archival data were validated prior to submission. Evaluating age; race; and grade of 
cancer (I, II, or III) in relation to mastectomy in MBC continues to limit investigations 
within cross-sectional or longitudinal frameworks.  
In addition, this study went through changes, as with any correlational research, 
primarily because of the rarity of MBC and difficulty finding data in the SEER database 
addressing the variables. Future investigators might consider giving more attention 
during the early stages to defining a construct in order to avert the same problems. Social 
change implications should include the provision of group counseling, emotional support, 
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